NCT04888364|Recruiting
French Parkinson's Disease Cohort - NS-PARK
NS-PARK
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
Loading search results
NS-PARK
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
Sponsor study identifier
Secondary identifiers
REGISTRY · RCB ID
observational
30,000
1 country
1
Study Start
June 16, 2021
Actual (reported)Primary Completion
December 31, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 19, 2021
Actual (reported)May 17, 2021
Actual (reported)June 16, 2021
Actual (reported)December 31, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Disease progression
Hoehn and Yahr score change
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Motor and non-motor complications
Occurence of motor (dyskinesia or motor fluctuations) or non-motor (dementia, dysautonomia, behavioral or psychiatric disorders, sleep disorders, falls, ...) complication
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Modification of antiparkinsonian treatment doses
Modification of antiparkinsonian treatment during follow-up will be measured as levodopa equivalent daily doses
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Predictive factorsof PD progression: motor or non motor symptoms
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Predictive factors of PD progression: genetic variants
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Predictive factors of PD progression: brain imaging markers
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Clusters of patients with similar disease progression profiles
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
Clusters of patients with similar genetic and disease progression profiles
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
All patients followed at one expert center for PD or associated centers in France.
Centre 01 Paris
Paris, 75013, France
Lanore A, Januel E, Bertille N, Fabbri M, Mariani LL, Mangone G, Sambin S, Menon PJ, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Dupont G, Moro E, Defebvre L, Houeto JL, Thobois S, Azulay JP, Geny C, Frismand S, Damier P, Giordana C, Castelnovo G, Ansquer S, De Maindreville AD, Drapier S, Maltete D, Tranchant C, Rascol O, Tubach F, De Rycke Y, Corvol JC; French NS-Park Network. Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort. CNS Drugs. 2025 Sep;39(9):879-891. doi: 10.1007/s40263-025-01193-5. Epub 2025 May 25.
Biosampling is optional and includes: * biosamples specifically collected for this research: blood samples (for DNA extraction and storage, peripheral white blood cells, and plasma); skin biopsy for isolation, culture and storage of fibroblasts; urine; saliva; * biosamples collected in clinical routine, part of it being stored for research purposes: CSF, salivari accessory gland biopsies.
Jean Christophe MD CORVOL, PU-PH
UMRS 1127
First Submitted
April 19, 2021
First Posted
May 17, 2021
Study Start
June 16, 2021
Actual (reported)Primary Completion
December 31, 2032
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Use and Misuse of Domperidone in Parkinson's Disease in France - Observational
Contact the study team to confirm eligibility.
Study Completion
December 31, 2034
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 20, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: